Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
The MINT trial demonstrates that inebilizumab markedly lowers exacerbation rates and rescue therapy use in AChR+ and MuSK+ generalized myasthenia gravis patients undergoing corticosteroid tapering.
The ADAM Study demonstrates superior diagnostic accuracy of live cell-based assays over fixed cell-based and ELISA tests for detecting AChR antibodies in myasthenia gravis, highlighting important clinical implications for antibody testing s
The ADAM study reveals that live and fixed cell-based assays outperform ELISA in detecting AChR and MuSK antibodies, offering enhanced diagnostic accuracy for myasthenia gravis, particularly in ocular cases.
A Bayesian network meta-analysis comparing FcRn inhibitors, C5 complement inhibitors, and CD19+ B-cell depletion therapies reveals comparable efficacy but varied safety profiles in generalized myasthenia gravis treatment, highlighting the n
This study reveals that LRP4 antibody-positive myasthenia gravis constitutes a distinct subgroup marked by higher disease severity and treatment escalation compared to other antibody-defined MG types, emphasizing its unique clinical managem
A large-scale multicenter study reveals that while patients with Guillain-Barré syndrome face significantly longer weaning times and higher tracheostomy rates than those with myasthenia gravis, both groups experience alarmingly high reintub
The FDA has approved inebilizumab-cdon (Uplizna) for adults with AChR- or MuSK-antibody positive generalized myasthenia gravis based on the phase 3 MINT trial showing a 1.9-point MG‑ADL improvement at 26 weeks versus placebo and sustained b
Phase 3 ADAPT SERON data show efgartigimod improves MG‑ADL scores in AChR‑Ab–negative gMG, with pronounced benefit in MuSK‑positive patients; results for triple‑seronegative disease were inconclusive. Safety profile was consistent with prio
A phase 3 trial shows inebilizumab, a CD19+ B-cell depleting antibody, improves function and reduces disease severity in generalized myasthenia gravis without increasing serious adverse events.